Investing

Pre-Market Stock News (October 15, 2007)

(APC) Anadarko filed for a spin-off of its Western Gas Partners LP.
(BIIB) Biogen-Idec trading up 18% after announcing it was putting itself up for sale.
(C) Citigroup $0.47 EPS vs. $0.44 est.; stock up 1% pre-market.
(CMED) China Medical Tech received Korean FDA approval for its HIFU system.
(CRA) Celera Genomics and collaboration team identified a risk score to predict genetic coronary disease.
(ELN) Elan hired Lehman for advice on Tysabri review extension from FDA; stock up over 10%.
(ETN) Eaton $1.67 EPS vs $1.68 est.
(GENZ) Genzyme presented positive results from Phase II of Alemtuzumab in Multiple Sclerosis studies.
(GLGC) Gene Logic agrees to sell its Genomics assets.
(MAT) Mattel $0.61 EPS vs $0.70 est, although that number includes some charges; stock down almost 1%.
(MDT) Medtronic suspended distribution of Sprint Fidelis(R) defibrillation leads on voluntary basis.
(NWS) News Corp.’s Fox Business News launches today.
(PCOP) Pharmacopeia acquired a selective androgen receptor modulator program from Bristol-Myers Squibb.
(PRM) Primedia put full year revenue guidance flat to low single digits versus previous "low single digit" guidance.
(TEK) Textronix gets $38 buyout from Danaher (DHR) in a $2.8 Billion deal.
(TELK) Telik said the FDA removed a partial hold on TELCYTA clinical development; stock up nearly 20%.
(VSAT) ViaSat was awared an $8.7 million contract to modernize Air Force telemetry tracking and control cryptographic units.
(WNG) Washington Group raised guidance.

Jon C. Ogg
October 15, 2007

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.